<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002584</url>
  </required_header>
  <id_info>
    <org_study_id>IGQ</org_study_id>
    <nct_id>NCT03002584</nct_id>
  </id_info>
  <brief_title>International Psychometric Validation Study of the Intestinal Gas Questionnaire (IGQ)</brief_title>
  <acronym>PRoVING</acronym>
  <official_title>International Psychometric Validation Study of the Intestinal Gas Questionnaire (IGQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Paris 7 - Denis Diderot</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EA 7334, Patient-Centered Outcomes Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Paris 7 - Denis Diderot</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To confirm the psychometrics properties of the Intestinal Gas Questionnaire (IGQ)
      in subjects with Irritable Bowel Syndrome (IBS) diagnosis and General population both
      complaining of Gas-Related Symptoms (GRS).

      IGQ has been developed previously simultaneously in UK English, French and Spanish through
      qualitative research with subject interviews. The conceptual framework of the IGQ assesses
      both GRS and their impact on daily life. Similar concepts were identified for both subjects
      with IBS diagnosis and general population and complaining of gas-related symptoms.

      The IGQ consists of a 24-hour recall symptom diary assessing 7 gas-related symptoms (17
      items) and a 7-day recall questionnaire which assesses the impact of those symptoms (26
      items)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational (non-interventional) study with a cross-sectional part for a subset of adult
      subjects with a single IGQ completion and a longitudinal cross-over part for a subset of
      subjects with test-retest IGQ completion for validation of electronic version of IGQ.

      300 eligible subjects (100 in each of the 3 countries: France, UK &amp; Spain):

        -  180 with IBS diagnosis (60% of recruited subjects)

        -  120 from General population (40% of recruited subjects)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric validation of the IGQ</measure>
    <time_frame>cross sectional for 70% of participants and test-retest within an interval of 7 days for 30% of participants</time_frame>
    <description>Stastistical analysis to confirm the psychometric validation of the IGQ questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electronic version of the IGQ</measure>
    <time_frame>During test-retest within an interval of 7 days</time_frame>
    <description>Comparison of scores between paper and electronic version of IGQ</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <condition>General Population</condition>
  <arm_group>
    <arm_group_label>IBS &amp; general population</arm_group_label>
    <description>The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.
Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).
Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>completion of self-reported questionnaires</intervention_name>
    <description>Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).
Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale</description>
    <arm_group_label>IBS &amp; general population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        IBS patients and subjects from general population complaining of Gas-Related Symptoms (GRS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All (subjects with IBS diagnosis and general population):

          -  Complaining of gas-related symptoms (GRS) of a certain severity level: subjects with
             IBS diagnosis and general population need to report a score of 4 or greater on at
             least one symptom on the symptom screening tool

          -  Cognitive and linguistic capability to complete several self-questionnaires

          -  BMI &gt; 18.5 and &lt; 30.0 kg/m2

          -  Agreement of the subject to participate in the study

        Subjects with IBS diagnosis:

          -  IBS diagnosis using Rome III diagnostic criteria for Functional Gastrointestinal
             Disorders (21)

          -  IBS severity: IBS-SSS score of 75 to 300

        General population:

          -  Subjects not fulfilling IBS Rome III criteria

          -  Regular stool frequency (i.e., between 3 and 21 bowel movements per week)

        Exclusion criteria

        All (subjects with IBS diagnosis and general population):

          -  Recent (2 last weeks) change in diet or intake of potentially flatulogenic compounds
             (fiber, lactulose)

          -  Organic gastrointestinal disease

          -  Other functional gastrointestinal disorder as defined by Rome III criteria

          -  Any severe and progressive disease (e.g. depression, cancer, uncontrolled diabetes,
             rheumatoid arthritis…)

          -  Any severe psychiatric disorder (e.g. acute episode of schizophrenia or bipolar
             disorder…)

          -  Pregnant women

          -  Being under the direct hierarchy of the investigatorBelonging to the site's staff team

        General population:

          -  Treatment for diarrhea or constipation including lactulose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Chassany, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>EA 7334, University Paris-Diderot, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Whorwell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>university of Manchester, Manchester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Azpiroz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit Coffin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Louis Mourier, Colombes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Duracinsky, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EA 7334, University Paris-Diderot, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de salud Chafarinas</name>
      <address>
        <city>Barcelona</city>
        <zip>08033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horta, Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Mèdic Sant Andreu</name>
      <address>
        <city>Barcelona</city>
        <zip>08740</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/nmo.12565/abstract</url>
    <description>Results of the qualitative analysis</description>
  </link>
  <reference>
    <citation>Chassany O, Tugaut B, Marrel A, Guyonnet D, Arbuckle R, Duracinsky M, Whorwell PJ, Azpiroz F. The Intestinal Gas Questionnaire: development of a new instrument for measuring gas-related symptoms and their impact on daily life. Neurogastroenterol Motil. 2015 Jun;27(6):885-98. doi: 10.1111/nmo.12565. Epub 2015 Apr 6.</citation>
    <PMID>25846412</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>December 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Paris 7 - Denis Diderot</investigator_affiliation>
    <investigator_full_name>Olivier CHASSANY</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>IBS, population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

